米氮平在治疗抑郁障碍中对患者睡眠改善观察

Observation on the Improvement of Sleep in Patients with Mirtazapine in the Treatment of Depressive Disorder

目的:探究米氮平在治疗抑郁障碍中对患者睡眠改善的效果。方法:选取2017年1月至2018年1月石家庄市第八医院收治的以失眠为主诉伴抑郁障碍患者67例,按照随机数字表法随机分为观察组33例和对照组34例。对照组患者给予舍曲林,观察组患者给予米氮平,共治疗8周。对2组患者治疗前后PSQI、HAMD-17评分、不良反应发生率和治疗效果进行比较。结果:治疗前,2组患者PSQI、HAMD-17评分差异无统计学意义(P> 0. 05);治疗后,2组患者PSQI、HAMD-17评分均降低,观察组显著低于对照组,差异有统计学意义(P <0. 05); 2组患者不良反应发生率比较,差异无统计学意义(P> 0. 05);观察组治疗总有效率较对照组高,差异有统计学意义(P <0. 05)。结论:米氮平可有效改善抑郁障碍患者睡眠状况,提高患者睡眠质量,值得临床借鉴。

Objective: To explore the effect of mirtazapine on sleep improvement in patients with depression. Methods: From January 2017 to January 2018,67 patients with insomnia and depression were randomly divided into observation group ( n =33) and control group ( n =34).The patients in the control group were treated with sertraline and the patients in the observation group were treated with mirtazapine for 8 weeks.The PSQI,HAMD-17 score,adverse reaction rate and therapeutic effect were compared between the two groups before and after treatment. Results: There was no significant difference in PSQI and HAMD-17 scores between the two groups before treatment ( P >0.05).After treatment,the PSQI and HAMD-17 scores of the two groups were decreased,and the observation group was significantly lower than the control group,the difference was statistically significant ( P <0.05).There was no significant difference in the incidence of adverse reactions between the two groups ( P >0.05).The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant ( P <0.05). Conclusion: Mirtazapine can effectively improve the sleep status of patients with depressive disorder and improve the quality of sleep of patients,which is worthy of clinical reference.